Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6872102 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6871747 | 0.99 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6871744 | 0.99 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6873181 | 0.77 | CYP4F2 (0.40) | SLC6A4USP14 | |
| SCHEMBL6870504 | 0.77 | CYP1A2 (0.41) | USP14 | |
| Hydrochloric Acid SCHEMBL6870704 | 0.76 | CYP1A2 (0.40) | USP14 | |
| SCHEMBL6871133 | 0.73 | USP14 (0.36) | SLC6A4USP14 | |
| SCHEMBL11116312 | 0.72 | CYP4F2 (0.47) | USP14 | |
| SCHEMBL6871136 | 0.71 | F10 (0.40) | USP14 | |
| SCHEMBL19706831 | 0.71 | SMYD3 (0.43) | USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | CHRNB4 4702/4885CHRNA3 4718/4885CHRNB2 4771/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | CHRNB4 4741/4885CHRNA3 4535/4885CHRNB2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.